Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real‐world analysis from the PETHEMA registry

Juan Manuel Alonso‐Domínguez; Tamara Castaño‐Bonilla; Cristina Gil; Josefina Serrano‐López; Pilar Martinez‐Sanchez; Pilar Herrera; Raimundo García‐Boyero; Eduardo Rodriguez‐Arboli; Joana Brioso‐Infante; Celina Benavente; Esperanza Lavilla‐Rubira; Mar Tormo; Maria J. Sayas‐Lloris; Daniel Láinez‐González; Juana Serrano‐Lopez; M. D. L. L. Amigo; Lorenzo Algarra Algarra; Ariane Unamunzaga; Jose M. Alonso‐Alonso; Maria C. Garcia‐Garay; Marta Callejas‐Charavia; Alicia Roldan‐Perez; Javier Cornago‐Navascues; Marta Valero‐Nuñez; Ana Alfonso‐Pierola; Esther Pérez‐Santaolalla; Marta Sobas; Monica Romero‐Riquelme; Miguel López; Kenny M. Gálvez; Rebeca Rodríguez‐Veiga; Eva Barragán; R. Ayala; Antonio Solana‐Altabella; Pilar Lloret‐Madrid; Pau Montesinos

doi:10.1002/cncr.70353

April 10, 2026Cancer

Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real‐world analysis from the PETHEMA registry

View at Publisher

Ask AI

Bookmark

Share

Key Points

The research aims to evaluate the prognosis of acute myeloid leukemia (AML) patients with BCR::ABL1 in light of tyrosine kinase inhibitors (TKIs).
Data analysis from the PETHEMA registry
Comparison of outcomes with and without TKI
Classification of patients into risk groups
Improved outcomes observed with TKI addition to chemotherapy
AML patients with BCR::ABL1 may benefit from re-classification to intermediate-risk
Findings suggest a need for larger studies to confirm results

Abstract

This study shows improved outcomes with the addition of TKI to chemotherapy and supports re-classification of AML patients harboring BCR::ABL1 in the intermediate-risk group. Nonetheless, given the small sample size, larger studies are needed to confirm these findings.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alonso‐Domínguez et al. (2026) studied this question.

synapsesocial.com/papers/69db37044fe01fead37c5071 https://doi.org/10.1002/cncr.70353

View at Publisher

Ask AI

Bookmark

Share

Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real‐world analysis from the PETHEMA registry

Key Points

Abstract

Discussion

Cite This Study

Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real‐world analysis from the PETHEMA registry

Key Points

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Cancer

Keep reading

More related papers

More from Cancer